FINWIRES · TerminalLIVE
FINWIRES

加拿大帝國商業銀行 (CIBC) 確認對 Celestica 的「跑贏大盤」評級,並將目標價上調至 425 美元,此前該公司公佈了第一季業績。

By

-- 在Celestica(CLS.TO,CLS)發布第一季財報前,加拿大帝國商業銀行資本市場維持對其對該股的「跑贏大盤」評級,並將目標股價從360美元上調至425美元。 該行表示,其仍然認為管理層對Celestica第一季和2026年的業績指引以及FactSet目前的共識預期“較為保守”,這反映出主要超大規模數據中心(GOOGL、META、AMZN)和OpenAI的資本支出計劃的透明度有所提高。該行指出,自2022年3月以來,Celestica的營收平均超出市場預期約5%,每股盈餘平均超出市場預期約10%。 該行也指出,2025年的業績預期比2024年10月發布的初步展望高出約20%。加拿大帝國商業銀行表示,近期發布的公告表明,這一趨勢仍在持續,並將原本應在2027年實現的客戶需求提前至2026年,這為其積極的投資邏輯提供了支撐。 CIBC 更新後的目標股價是基於其 2027 年每股盈餘 (EPS) 預期值的 32 倍和 2027 年息稅折舊攤銷前利潤 (EBITDA) 預期值的 24 倍綜合估值。 分析師 Todd Coupland 表示:“我們認為,這一調整得益於前景的改善,並且與網絡和 EMS 同行估值普遍上漲的情況基本一致。我們上調了 Celestica 的目標倍數,以反映其人工智能數據中心資本支出預期上調的前景更加明朗,這得益於模型性能的顯著提升。” (報告北美、亞洲和歐洲主要銀行及研究機構的股票、大宗商品和經濟研究。研究機構可透過以下連結與我們聯繫:https://www..com/contact-us

Price: $532.84, Change: $+27.72, Percent Change: +5.49%

Related Articles

Treasury

Scotiabank Previews This Week's February and Preliminary March GDP for Canada

Canada reports gross domestic product for February and the preliminary estimate for March on Thursday, said Scotiabank.February was initially guided by Statistics Canada to have been tracking a 0.2% month-over-month gain last month. Updated estimates are still in the same ballpark, but investors also get important details on sector drivers, noted the bank.More meaningful may be the flash guidance, with no details, for March GDP, for which there is very little information so far, but a small gain is "feasible," stated Scotiabank.The outcome will further inform Q1 GDP growth tracking on a production/income basis using monthly GDP. It's feasible that growth is tracking close to the Bank of Canada's 1.8% January Monetary Policy Report estimate, but that's on an expenditure basis. The massive over 4% inventory drag on Q4 GDP could reverse as an added upside, pointed out the bank.One key is that consumer spending on goods is tracking a strong rebound in Q1 based on retail sales volumes. It's untrue that the economy isn't exhibiting rate sensitivity, a view that is disproportionately driven by a false understanding of what's keeping condo markets weak in Toronto and Vancouver, added Scotiabank.

$$CXY
Australia

Vicor Insider Sold Shares Worth $2,079,226, According to a Recent SEC Filing

Alvaro Doyle, Vice President and Chief Information Officer, on April 23, 2026, sold 8,000 shares in Vicor (VICR) for $2,079,226. Following the Form 4 filing with the SEC, Doyle has control over a total of 42 common shares of the company, with 42 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/751978/000182673026000002/xslF345X05/primary_doc.xmlPrice: $265.29, Change: $-8.24, Percent Change: -3.01%

$VICR
Australia

BioMarin Seen Building Broader Rare-Disease Platform After Amicus Deal, Morgan Stanley Says

BioMarin Pharmaceutical (BMRN) is emerging as a broader rare-disease platform as its acquisition of Amicus Therapeutics (FOLD) adds two approved medicines and reduces reliance on Voxzogo, Morgan Stanley said Monday in a report.The Amicus deal reshapes BioMarin's outlook by adding Galafold and Pombiliti with Opfolda, products that fit the company's global commercial network, the report said. The therapies are expected to generate more than $1.3 billion in revenue by 2030, Morgan Stanley said.The acquisition is projected to accelerate revenue growth immediately after closing and to be accretive to non-GAAP earnings within 12 months, with "substantial accretion" beginning in 2027, the report said. BioMarin closed its $4.8 billion purchase of Amicus on Monday.Morgan Stanley resumed coverage on BioMarin stock with an overweight rating and a $120 price target.Price: $54.08, Change: $+0.90, Percent Change: +1.68%

$BMRN$FOLD